Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20766493 | 1.00 | HTR2A (1.00) | HTR2AHTR2C | |
| SCHEMBL20767317 | 0.91 | HTR2A (1.00) | HTR2A | |
| SCHEMBL23312340 | 0.91 | HTR2A (1.00) | HTR2A | |
| SCHEMBL20767109 | 0.89 | HTR2A (1.00) | HTR2AHTR2C | |
| SCHEMBL20767087 | 0.89 | HTR2A (1.00) | HTR2AHTR2C | |
| SCHEMBL20766820 | 0.89 | HTR2A (0.80) | HTR2AHTR2C | |
| SCHEMBL20765920 | 0.89 | HTR2A (0.80) | HTR2AHTR2C | |
| SCHEMBL20765905 | 0.89 | HTR2A (0.80) | HTR2AHTR2C | |
| SCHEMBL20765849 | 0.87 | HTR2A (0.78) | HTR2AHTR2C | |
| SCHEMBL20766162 | 0.87 | HTR2A (0.78) | HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210122713-A1 | COMPOUNDS, SALTS THEREOF AND METHODS FOR TREATMENT OF DISEASES | ACADIA PHARMACEUTICALS INC. (US) | 2021-04-29 | — | — | US | claimed |
| EP-3672960-A2 | COMPOUNDS, SALTS THEREOF AND THEIR USE FOR THE TREATMENT OF DISEASES | Acadia Pharmaceuticals Inc. (US) | 2020-07-01 | — | — | EP | claimed |
| WO-2019040104-A2 | COMPOUNDS, SALTS THEREOF AND METHODS FOR TREATMENT OF DISEASES | ACADIA PHARMACEUTICALS INC. (US) | 2019-02-28 | — | — | WO | claimed |
| US-11440884-B2 | Compounds, salts thereof and methods for treatment of diseases | ACADIA PHARMACEUTICALS INC. (US) | 2022-09-13 | — | — | US | disclosed |
| US-20210122713-A1 | COMPOUNDS, SALTS THEREOF AND METHODS FOR TREATMENT OF DISEASES | ACADIA PHARMACEUTICALS INC. (US) | 2021-04-29 | — | — | US | disclosed |
| US-20210122713-A1 | COMPOUNDS, SALTS THEREOF AND METHODS FOR TREATMENT OF DISEASES | ACADIA PHARMACEUTICALS INC. (US) | 2021-04-29 | — | — | US | disclosed |
| EP-3672960-A2 | COMPOUNDS, SALTS THEREOF AND THEIR USE FOR THE TREATMENT OF DISEASES | Acadia Pharmaceuticals Inc. (US) | 2020-07-01 | — | — | EP | disclosed |
| WO-2019040104-A2 | COMPOUNDS, SALTS THEREOF AND METHODS FOR TREATMENT OF DISEASES | ACADIA PHARMACEUTICALS INC. (US) | 2019-02-28 | — | — | WO | disclosed |
| WO-2019040104-A2 | COMPOUNDS, SALTS THEREOF AND METHODS FOR TREATMENT OF DISEASES | ACADIA PHARMACEUTICALS INC. (US) | 2019-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11440884-B2 | Compounds, salts thereof and methods for treatment of diseases | SLC10A1, VHL, CYP11B2 | HTR2A 4030/4885HTR2C 3822/4885 |
| US-20210122713-A1 | COMPOUNDS, SALTS THEREOF AND METHODS FOR TREATMENT OF DISEASES | SLC10A1, VHL, CYP11B2 | HTR2A 4030/4885HTR2C 3822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.